CD8-Positive T-Lymphocytes
"CD8-Positive T-Lymphocytes" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A critical subpopulation of regulatory T-lymphocytes involved in MHC Class I-restricted interactions. They include both cytotoxic T-lymphocytes (T-LYMPHOCYTES, CYTOTOXIC) and CD8+ suppressor T-lymphocytes.
Descriptor ID |
D018414
|
MeSH Number(s) |
A11.118.637.555.567.569.220 A15.145.229.637.555.567.569.220 A15.382.490.555.567.569.220
|
Concept/Terms |
CD8-Positive T-Lymphocytes- CD8-Positive T-Lymphocytes
- CD8 Positive T Lymphocytes
- CD8-Positive T-Lymphocyte
- T-Lymphocyte, CD8-Positive
- T-Lymphocytes, CD8-Positive
- T8 Lymphocytes
- Lymphocyte, T8
- Lymphocytes, T8
- T8 Lymphocyte
- T8 Cells
- Cell, T8
- Cells, T8
- T8 Cell
- CD8-Positive Lymphocytes
- CD8 Positive Lymphocytes
- CD8-Positive Lymphocyte
- Lymphocyte, CD8-Positive
- Lymphocytes, CD8-Positive
Suppressor T-Lymphocytes, CD8-Positive- Suppressor T-Lymphocytes, CD8-Positive
- CD8-Positive Suppressor T-Lymphocyte
- CD8-Positive Suppressor T-Lymphocytes
- Suppressor T Lymphocytes, CD8 Positive
- Suppressor T-Lymphocyte, CD8-Positive
- T-Lymphocyte, CD8-Positive Suppressor
- T-Lymphocytes, CD8-Positive Suppressor
- Suppressor T-Cells, CD8-Positive
- CD8-Positive Suppressor T-Cell
- CD8-Positive Suppressor T-Cells
- Suppressor T Cells, CD8 Positive
- Suppressor T-Cell, CD8-Positive
- T-Cell, CD8-Positive Suppressor
- T-Cells, CD8-Positive Suppressor
|
Below are MeSH descriptors whose meaning is more general than "CD8-Positive T-Lymphocytes".
Below are MeSH descriptors whose meaning is more specific than "CD8-Positive T-Lymphocytes".
This graph shows the total number of publications written about "CD8-Positive T-Lymphocytes" by people in this website by year, and whether "CD8-Positive T-Lymphocytes" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 0 | 5 | 5 |
1995 | 2 | 8 | 10 |
1996 | 3 | 2 | 5 |
1997 | 2 | 2 | 4 |
1998 | 3 | 7 | 10 |
1999 | 3 | 3 | 6 |
2000 | 4 | 9 | 13 |
2001 | 4 | 2 | 6 |
2002 | 9 | 3 | 12 |
2003 | 11 | 11 | 22 |
2004 | 9 | 10 | 19 |
2005 | 18 | 9 | 27 |
2006 | 18 | 9 | 27 |
2007 | 15 | 16 | 31 |
2008 | 13 | 14 | 27 |
2009 | 19 | 11 | 30 |
2010 | 9 | 14 | 23 |
2011 | 15 | 8 | 23 |
2012 | 14 | 14 | 28 |
2013 | 17 | 9 | 26 |
2014 | 14 | 21 | 35 |
2015 | 10 | 9 | 19 |
2016 | 11 | 12 | 23 |
2017 | 18 | 16 | 34 |
2018 | 13 | 21 | 34 |
2019 | 25 | 24 | 49 |
2020 | 17 | 29 | 46 |
2021 | 18 | 32 | 50 |
2022 | 13 | 29 | 42 |
2023 | 10 | 27 | 37 |
2024 | 0 | 5 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "CD8-Positive T-Lymphocytes" by people in Profiles.
-
Inhibition of MER proto-oncogene tyrosine kinase by an antisense oligonucleotide enhances treatment efficacy of immunoradiotherapy. J Exp Clin Cancer Res. 2024 Mar 06; 43(1):70.
-
Single-Cell CD4 and CD8 T-Cell Secretome Profiling Reveals Temporal and Niche Differences in Acute Myeloid Leukemia Following Immune Checkpoint Blockade Therapy. Cancer Res Commun. 2024 03 06; 4(3):671-681.
-
Targeting ALK averts ribonuclease 1-induced immunosuppression and enhances antitumor immunity in hepatocellular carcinoma. Nat Commun. 2024 Feb 02; 15(1):1009.
-
PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-?B Signaling in Patients with Pancreatic Cancer. Clin Cancer Res. 2024 02 01; 30(3):542-553.
-
Antigen-presenting B cells promote TCF-1+ PD1- stem-like CD8+ T-cell proliferation in glioblastoma. Front Immunol. 2023; 14:1295218.
-
Autologous engineered T cell receptor therapy in advanced cancer. Hum Vaccin Immunother. 2023 Dec 15; 19(3):2290356.
-
Anti-CD19/CD8 bispecific T cell engager for the potential treatment of B cell malignancies. Cell Immunol. 2023 Nov-Dec; 393-394:104787.
-
Generation of Non-Alloreactive Antiviral Central Memory CD8 Human Veto T Cells for Cell Therapy. Transplant Cell Ther. 2024 Jan; 30(1):71.e1-71.e13.
-
SARS-CoV-2 infection establishes a stable and age-independent CD8+ T cell response against a dominant nucleocapsid epitope using restricted T cell receptors. Nat Commun. 2023 10 23; 14(1):6725.
-
Upregulation of exosome secretion from tumor-associated macrophages plays a key role in the suppression of anti-tumor immunity. Cell Rep. 2023 10 31; 42(10):113224.